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DOI 10.1016/j.immuni.2011.05.015SUMMARY been observed in mucosal biopsies from patients with inflamma-Thymic stromal lymphopoetin (TSLP) influences
numerous immune functions, including those in the
colonic mucosa. Here we report that TSLP-deficient
(Tslp/) mice did not exhibit increased inflammation
during dextran sodium sulfate (DSS)-induced colitis
but failed to recover from disease, resulting in death.
Increased localized neutrophil elastase (NE) activity
during overt inflammation was observed in Tslp/
mice and was paralleled by reduced expression of
an endogenous inhibitor, secretory leukocyte pepti-
dase inhibitor (SLPI). Pharmacological inhibition of
NE or treatment with rSLPI reduced DSS-induced
mortality in Tslp/ mice. Signaling through TSLPR
on nonhematopoietic cells was sufficient for
recovery from DSS-induced colitis. Expression of
the receptor occurred on intestinal epithelial cells
(IEC), with stimulation inducing SLPI expression.
Therefore, TSLP is critical inmediatingmucosal heal-
ing after insult and functions in a nonredundant
capacity that is independent of restraining T helper
1 (Th1) and Th17 cell cytokine production.
INTRODUCTION
Thymic stromal lymphopoetin (TSLP) is critical in the regulation
of numerous immunological processes. These include, but are
not limited to, conditioning of dendritic cells (DCs) to drive Th2
skewing of T cells (Ito et al., 2005), enhanced class switching
in B cells (Xu et al., 2007), and induction of Foxp3+ regulatory T
(Treg) cells in humans (Watanabe et al., 2005) but not mice
(Sun et al., 2007). TSLP expression is increased in immunopa-
thologies with dysregulated Th2 cell-type cytokine production
including atopic dermatitis (Soumelis et al., 2002) and asthma
(Ying et al., 2005). Although the pathophysiological features of
these diseases can be recapitulated in mice overexpressing
TSLP (Headley et al., 2009), decreased production of TSLP hastory bowel disease (IBD) (Rimoldi et al., 2005). Regulation of
TSLP is dependent on the transcription factor NF-kB and is
induced by exposure to bacteria (Rimoldi et al., 2005), agonists
of toll-like receptor (TLR) or the intracellular sensor NOD (Lee
and Ziegler, 2007; Zaph et al., 2007), and cytokines including
TNF-a (Lee et al., 2008). Initially suggested as a mechanism to
allow the commensal microbiota to induce tolerance, TSLP
produced by intestinal epithelial cells is not required for tolero-
genic mucosal DC and Treg cell generation (Iliev et al., 2009).
Although the etiology of IBD has remained elusive, immunopa-
thology results from loss of immunosuppressive or enhanced
production of proinflammatory factors. Self-resolving immuno-
pathology that recapitulates the hallmarks of colitis in patients
can be induced in mice by addition of dextran sodium sulfate
(DSS) to drinking water. Inflammation in this model is due to
epithelial cell apoptosis, increasing recruitment, and activation
of macrophages (Tlaskalova´-Hogenova´ et al., 2005), DCs
(Berndt et al., 2007), and neutrophils (Okayasu et al., 1990).
Although T cell activation and mucosal homing occur, T cells
are not necessary for disease (Katakura et al., 2005). The result-
ing inflammation is associated with structural changes in the
colon as a result of increased activity of proteases including
neutrophil elastase (NE) and metallomatrix proteases (MMPs)
(Castaneda et al., 2005).
Recovery after inflammation is a complex process requiring
not only suppression of immune processes but also balance
between proteolytic enzymes and their endogenous inhibitors.
Secretory leukocyte peptidase inhibitor (SLPI) is induced by
microbial products, functioning as a serine protease inhibitor,
antimicrobial peptide, and inhibitor of NF-kB (Taggart et al.,
2005). SLPI is increased during resolution from DSS colitis (Miz-
oguchi et al., 2003) and exerts a nonredundant role after injury,
as indicated by the fact that SLPI deficiency reduces cutaneous
wound healing (Ashcroft et al., 2000).
TSLP in the gastrointestinal tract has been described to inhibit
Th1 cell type cytokine production after insult. Although in a
previous publication increased IFN-g production was observed
in mice deficient for the TSLP receptor (Crlf2/), potentiating
the severity of DSS colitis (Taylor et al., 2009), here we report
that deficiency in TSLP ligand did not increase colitis severityImmunity 35, 223–235, August 26, 2011 ª2011 Elsevier Inc. 223
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Figure 1. TSLP Deficiency Does Not
Enhance Colitis Severity but Does Prevent
Recovery
Inflammation was assessed in DSS-treated
Tslp/ mice by (A) macroscopic disease, (B)
colon length, (C) serum SAA concentration, (D and
E) histological damage, (F) weight loss, and (G)
survival. Graphs indicate control (open bars), DSS
(solid bars); mean ± SD, n = 10–15 mice/group;
scale bar represents 50 mm; *p < 0.05, ANOVA.
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TSLP Is Required for Recovery after Colitisbut prevented recovery from disease. Recovery from colitis
occurred through signaling transduced by TSLPR on radio-
resistant host cells, as indicated by the fact that mortality was
not increased in Crlf2+/+ mice reconstituted with Crlf2/ bone
marrow (BM). Our data demonstrate that TSLP functions as a
critical mediator controlling the balance between host defense
and wound repair, without constraining production of Th1
cytokines.
RESULTS
Deficiency in TSLP Does Not Alter Immune Cell
Development
The requirement for TSLP in the development and maintenance
of B and T cell populations was assayed in TSLP wild-type
(Tslp+/+), and deficient (Tslp/) mice. Consistent with a lack of
a requirement for TSLP in murine Treg cell development (Sun
et al., 2007), equivalent numbers of CD4+Foxp3+ cells were
found in the spleen and mesenteric lymph nodes (MLNs) (see
Figure S1A available online) in Tslp+/+ and Tslp/ mice. This
was mirrored by equivalent colonic Foxp3 expression in both
genotypes by qRT-PCR (Figure S1B). TSLP deficiency did not
alter the number of DCs (CD11b+CD11c+, CD11bCD11c+, or
CD11cloPDCA-1+) in the spleen or MLN, or increase activation,224 Immunity 35, 223–235, August 26, 2011 ª2011 Elsevier Inc.as assessed by CD40, CD80, and CD86
(Figures S1C and S1D). In addition, we
noted no spontaneous inflammation in
mice aged for 18 months. Thus, the
absence of TSLP does not favor the
development of spontaneous inflamma-
tion or autoimmunity.
Lack of TSLP Prevents Recovery
from DSS-Induced Colitis
In the absence of spontaneous inflamma-
tion, we sought to determine whether the
lack of TSLP would enhance the severity
of an inducedcolonic inflammation. Unlike
the increased susceptibility reported in
Crlf2/ mice (Taylor et al., 2009), the
severity of DSS colitis was equivalent in
Tslp/ and Tslp+/+ mice. Macroscopic
score, colon length, concentration of the
acute phase protein serum amyloid A
(SAA), and histological damage scores
were not increased in Tslp/ compared
to Tslp+/+ mice at 8 days post-DSS(Figures 1A–1E). When Tslp+/+ mice began to recover 9–10 days
post-DSS, TSLP deficiency prevented recovery from inflamma-
tion (Figure 1F). Progressive weight loss and inability to recover
met predefined humane endpoints, requiring sacrifice beginning
on day 9, with no Tslp/ mice surviving 14 days post-DSS (Fig-
ure 1G). Peripheral blood analysis indicated no anemia or throm-
bocytopenia in all genotypes (Table S1). Accelerated disease
progression was also excluded; Tslp/ mice assessed 4 days
post-DSS did not display increased inflammation compared to
Tslp+/+ (Figures S2A and S2B). We further excluded increased
susceptibility to DSS, because a lower dose (3% w/v) produced
equivalent weight loss, colon shortening, and macroscopic and
histological damage scores in Tslp/ and Tslp+/+ mice (Figures
S2C and S2D and data not shown). Therefore, lack of TSLP
does not result in enhancement of inflammation, but impairs
recovery from disease.
To ascertain whether the lack of enhanced colonic inflamma-
tion was unique to Tslp/ mice, we subjected mice lacking
TSLP receptor (Crlf2/) to DSS colitis. Onset of disease by
weight loss, macroscopic score, colon length, and histological
examination indicated equivalent morbidity in Crlf2/
compared to WT or Tslp/ mice (Figures S2E and S2F and
data not shown). However, Crlf2/ mice experience signifi-
cantly increased mortality compared to DSS-treated WT mice
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Figure 2. Deficiency in TSLP Signaling Does
Not Enhance T Cell-Dependent Colitis
FACS-sorted CD4+CD45RBhi (Teff) ± CD4+
CD45RBlo cells from Crlf2+/+ or Crlf2/ were
transferred to Rag1/ recipients and monitored
for (A) weight loss, (B) macroscopic disease, (C)
colon length, and (D and E) histological damage
(n = 4–5 mice/group). Scale bar represents 50 mm.
(F) STAT5 phosphorylation was assessed after
stimulationwith rmIL-7 inCD4+orCD8+Tcells from
Crlf2/, Tslp/, or WT (n = 3) mice (mean ± SD).
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TSLP Is Required for Recovery after Colitis(Figure S2G). Thus, lack of TSLP or TSLPR reduces the ability to
recover from colonic insult without enhanced inflammation.
In order to determine whether these data were specific to the
DSS model, we utilized a T cell-dependent model of colitis.
Disease was induced by adoptive transfer of FACS-sorted CD4+
CD45RBhi effector T (Teff) cells intoRag1/mice, with the effec-
tiveness of Treg cell assessed by cotransfer of CD4+CD45RBlo
cells. Transfer of Teff cells from Crlf2+/+ or Crlf2/mice resulted
in weight loss 5 weeks posttransfer (Figure 2A). Disease onset,
macroscopic score, colon length, and histological scores were
similar between recipients of Crlf2+/+ or Crlf2/ T cells (Figures
2A–2E). Recipients of Teff + Treg cells from Crlf2+/+ or Crlf2/
mice appeared healthy upon necropsy. Moreover, Treg cells
from Crlf2/ mice remain effective in vivo against WT Teff cells
as indicated by the fact that recipients of Crlf2+/+ Teff + Crlf2/
Treg cells did not develop disease (Figures 2A–2E). These data
demonstrate that TSLP signaling in T cells does not influence
the development of T cell-dependent colitis and that Treg cell
function is not diminished by deficiency in TSLPR.
Because TSLP binds a heterodimer of TSLPR and IL-7Ra and
IL-7 can increase colitis severity (Okada et al., 2005), we investi-
gated whether lack of TSLP or TSLPR altered IL-7 signaling.
Stimulation of isolated splenocytes with rmIL-7 induced equiva-
lent STAT5 phosphorylation in CD4+ and CD8+ T cells from WT,
Tslp/, and Crlf2/ mice (Figure 2F). Together, these dataImmunity 35, 223–235demonstrate that absence of TSLP-
evoked signaling in T cells does not influ-
ence the development of a T cell-depen-
dent colitis, that Treg cell function is not
diminished by deficiency in TSLPR, and
that lack of enhanced inflammation is
not specific to innate or adaptive immune
models of colitis.
Prevention of Recovery in Tslp–/–
Mice Is Not Mediated by Cytokine
Skewing
Previous work conducted on Crlf2/
mice implied that increased Th1 type
cytokines produced during DSS-induced
colitis enhanced the severity of disease.
To ascertain whether delayed recovery
was due to dysregulated Th1-type cyto-
kine production, the immune response
to DSS was characterized by several
complementary techniques. Cytokinescharacteristic of Th1, Th2, and Th17 immune responses were
evaluated in the serum and colons of mice 8 days post-DSS.
Mice with overt inflammation had significantly increased serum
concentrations (Figure 3A) and colonic mRNA (Figure 3B) for
IFN-g, IL-4, IL-6, IL-10, IL-17, TNF-a, and KC. No differences
were observed between the two genotypes at baseline or during
inflammation (Figures 3A and 3B). CD4+ T cells from the spleen
or MLN also produced equivalent amounts of IFN-g after
in vitro restimulation irrespective of genotype (data not shown).
Therefore, the initial severity of intestinal inflammation and cyto-
kine production is not simply enhanced in the absence of TSLP.
We further assessed whether lack of TSLP would impact
systemic immune functions by analyzing the response after
immunization with OVA. Injection of OVA:CFA or OVA:Alum
induced potent Th1 and Th2 cell responses, respectively.We de-
tected no difference in OVA-specific IgG1 (Figure S3A) or IgG2a
(Figure S3B) antibody titers in Tslp/ mice compared to Tslp+/+
controls. These data clearly indicate that lack of TSLP alone
does not increase the production of Th1 type cytokines, basally
or after the induction of an immune response.
TSLP Deficiency Does Not Impair Intestinal Barrier
Function or Alter the Colonic Microbiota
Given the role of mucosal barrier dysfunction in IBD, it was
conceivable that delayed recovery may be due to prolonged, August 26, 2011 ª2011 Elsevier Inc. 225
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Figure 3. Lack of TSLP Does Not Increase
Th1 Type Cytokines during DSS Colitis
Cytokine production was assessed in (A) serum by
cytometric bead array (*p < 0.05, ANOVA; n = 8–12
mice/group) or (B) qRT-PCR on colonic tissue after
DSS colitis (mean ± SD, n = 8 mice/group, data
normalized to GAPDH; control [open bars], DSS
[solid bars]; *p < 0.05, t test).
Immunity
TSLP Is Required for Recovery after Colitisexposure to luminal contents, resulting in sustained immune
activation. Intestinal barrier function was assessed by transloca-
tion of viable bacteria to the MLN and spleen or by detection of
gavaged FITC-conjugated dextran probe in the serum. Tslp/
mice did not have a basal intestinal barrier defect; naive mice
displayed no increased bacterial translocation to the MLN (Fig-
ure S4A) or spleen (Figure S4B) compared to Tslp+/+ mice. In
contrast, increased bacterial translocation to the MLN and
spleen was observed in all mice treated with DSS, irrespective
of genotype. Similarly, translocation of FITC-dextran from the
lumen to the blood was not enhanced in naive Tslp/ mice
compared to Tslp+/+ controls, whereas DSS significantly
enhanced permeability in both genotypes (Figure S4C).
In addition to the IEC monolayer and tight junction proteins
between adjacent cells, the mucosal barrier is also comprised
of secreted IgA and mucous produced by goblet cells. There226 Immunity 35, 223–235, August 26, 2011 ª2011 Elsevier Inc.was no reduction in the numbers of IgA+
B cells in the Peyer’s patches (Figure S4D)
or in luminal or serum IgA (data not shown)
in Tslp/ mice. No difference in the
number of goblet cells was observed in
the colon or terminal ileum of naive
Tslp/ mice (Figures S4E and S4F).
Although DSS treatment reduced the
number of colonic goblet cells, there was
no difference between genotypes. Defi-
ciency in TSLP does not reduce intestinal
barrier function at baseline or during
inflammation.
To determine the impact of TSLP or
TSLPR deficiency on the microbiota
composition, we used qRT-PCR for
selected bacterial 16S rDNA. No signifi-
cant differences in the microbiota were
observed in comparing naive or DSS-
treated WT, Tslp/, or Crfl2/ mice.
Treatment with DSS colitis did, however,
significantly reduce segmented filamen-
tous bacteria (SFB) to below the limit of
detection (Figure S4G). With this method,
we detected no Salmonella sp. or Helico-
bacter sp., bacteria known to exacerbate
or induce murine colitis (data not shown).
TSLP ligand or receptor deficiency does
not appear to alter the composition of the
colonic microbiota in health or disease.
To assess whether macrophage or
neutrophil recruitment was reduced in
Tslp/ mice, immunohistochemistry (IHC)
was conducted. Similar numbers of these cells were observed in
the colon after DSS colitis in Tslp/ and WT mice (data not
shown). Neutrophil recruitment after i.p. injection of LPS or the
NOD2agonistMDP-induced equivalent recruitment of neutrophils
into the peritoneum of WT and Tslp/ mice (data not shown).
Together, these data indicate that the absence of TSLP does not
impair host defenses after breach of the epithelial barrier.
TSLP Deficiency Reduces SLPI Expression during
Recovery from Disease
In order to determine the defect preventing Tslp/ mice from
recovering after DSS colitis, we performed qRT-PCR on colonic
samples for genes critical to resolution of inflammation. Expres-
sion of Annexin A1 (ANXA1), PTGES2, iNOS (NOS2), the negative
regulators of NF-kB signaling IRAKM, and TNFAIP3 were
increased in all genotypes after DSS administration (Figure 4A).
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Figure 4. Reduced Expression of the
Protease Inhibitor SLPI in the Absence of
TSLP
(A) Gene expression in colonic tissue was as-
sessed by qRT-PCR (mean ± SD, n = 10–15 mice/
group; control [open bars], DSS [solid bars]; *p <
0.05, ANOVA).
(B) Mason’s trichrome staining for collagen (blue)
on colonic tissues from control and DSS-treated
Tslp+/+ and Tslp/ mice. 203 magnification is
from red rectangle; 6 mice/group; scale bar
represents 50 mm.
(C) SLPI expression was determined by immuno-
blotting colonic homogenates (n = 6 mice/group).
(D and E) MMP (D) and NE (E) activity in colonic
homogenates was assessed by a substrate
cleavage assay (mean ± SD, n = 4–9 mice/group;
control [open symbols], DSS [solid symbols]; *p <
0.05 by ANOVA).
(F) PGRNwas determined in colonic homogenates
by immunobloting (n = 6 mice/group).
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TSLP Is Required for Recovery after ColitisWe also detected no difference in TNFAIP8, TFF3, REGIIIb and
REGIIIg, lipoxygenases (ALOX5, ALOX12, ALOX15), and genes
expressed by alternatively activated macrophages: Arg1,
Mrc1, Chi3l3, and Fizz1 between genotypes (Figure S5). In
contrast, expression ofSlpi (encoding secretory leukocyte pepti-
dase inhibitor) mRNA was significantly upregulated after DSS
colitis in Tslp+/+ but not Tslp/ mice (Figure 4A) and confirmed
by immunoblot on full thickness colon homogenates (Figure 4C).
Several mechanisms have been ascribed to how SLPI aids in
resolution from injury, including the inhibition of proteases.
Consistent with increased protease activity, colonic sections
from DSS-treated Tslp/ mice showed defined regions below
IEC with reduced collagen (blue staining, area indicated by
asterisk in Figure 4B). Both MMPs and NE can degrade extracel-
lular membrane (ECM) components, although SLPI has been
demonstrated to inhibit NE. With a nonselective MMP assay,
increased colonic MMP activity was detected 8 days post-Immunity 35, 223–235DSS, but no differences between geno-
types was observed (Figure 4D). In
a similar fashion, use of a NE-selective
substrate demonstrated significantly
increased colonic NE activity in Tslp/
mice 8 days post-DSS compared to WT
(Figure 4E). Increased NE activity was
not due to enhanced NE expression
(Elane, Figure 4A), neutrophilia, or recruit-
ment after DSS in Tslp/ mice (data not
shown).
NE is known to degrade a number of
substrates in vivo. Included in these is
progranulin (PGRN), a protein that aids
wound healing unless degraded by NE.
Whereas increased PGRN protein
expression occurred during inflammation
in WT mice, decreased protein but not
mRNA expression was observed in
Tslp/ mice (Figures 4A and 4F). In the
absence of TSLP, increased NE activity after colonic inflamma-
tion causes PGRN degradation, a protein critical to wound
repair.
Inhibition of NE Allows for Recovery from DSS Colitis
in Tslp–/– Mice
To assess how increased NE activity and lack of SLPI contrib-
uted to increased mortality in Tslp/mice, a selective NE inhib-
itor (NEi), SSR69071, was used. Mice were subjected to DSS
colitis and orally gavaged with SSR69071, beginning on day 6,
prior to the recovery phase. SSR69071 treatment significantly
reduced mortality in Tslp/ mice compared to vehicle control
(Figure 5A). Disease was not altered in Tslp+/+ mice, indicating
that SSR69071 does not simply reduce the severity of colitis.
To ascertain whether lack of SLPI alone led to increased NE
activity and mortality, Tslp/ mice were treated with rSLPI or
vehicle at the beginning of recovery. Gavage of rSLPI, August 26, 2011 ª2011 Elsevier Inc. 227
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Figure 5. Inhibition of NE Reduces DSS-Induced Mortality in TSLP–/– Mice
(A) DSS-treated Tslp/ or WT mice were gavaged with the NE inhibitor SSR69071 (3 mg/kg) or vehicle from day 6 to day 14 and monitored for (top) weight loss
and (bottom) mortality.
(B) In separate experiments, mice were gavaged with rSLPI (B) and assessed for (top) weight loss and (bottom) mortality.
(C–E) IEC proliferation as determined by colonic Ki67 staining after 4 days of treatment (day 10 post-DSS) with vehicle or SSR69071, and (D) apoptosis in Tslp+/+
and Tslp/ DSS-treated mice.
(F) Colonic PGRN was determined on full thickness tissue homogenates 10 days post-DSS (mean ± SD, n = 4 mice/group; *p < 0.05, ANOVA).
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TSLP Is Required for Recovery after Colitissignificantly reduced mortality in Tslp/ mice after DSS colitis
(Figure 5B). These data demonstrate that enhanced NE activity
in Tslp/ mice, resulting from the absence of SLPI, prevents
colonic healing after insult.
Inhibition of NE by SSR69071 and the impact on newly synthe-
sized (non-cross linked) collagen was assessed by the Sircol
collagen assay. Nascent collagen was significantly increased228 Immunity 35, 223–235, August 26, 2011 ª2011 Elsevier Inc.after DSS administration of Tslp+/+ but not Tslp/mice. NE inhi-
bition had no effect in Tslp+/+ but significantly increased collagen
in Tslp/ mice compared to vehicle control (Figure S6A).
Expression of prominent intestinal collagen progenes assayed
for by qRT-PCR indicated increased expression of Col1a1 in
Tslp+/+ and Tslp/ mice 8 days post-DSS, irrespective of NEi
treatment (Figure S7). Significantly increased expression of
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(A) Confocal microscopy was performed for TSLP
(blue), SLPI (red), and E-cadherin+ IEC (green) in
Tslp+/+ mice (asterisks, top) and Tslp/ mice
(daggers, bottom) (arrows, L, lumen; scale bar
represents 20 mm).
(B–F) WT mice reconstituted with Crlf2+/+ or
Tslp/BMwere subjected to colitis and assessed
by (B) weight loss, (C) colon length, (D) Mason’s
trichrome staining, (E) histological damage, and (F)
SLPI expression (mean ± SD; scale bar represents
100 mm; n = 3–4 mice/group; control [open bars],
DSS [solid bars]; *p < 0.05, **p < 0.001, ANOVA).
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TSLP Is Required for Recovery after ColitisCol4a2was also observed in DSS-treated Tslp/mice receiving
vehicle or SSR69071.We also noted reducedCol1a1 andCol4a1
after DSS administration, but this was again independent of
genotype or NEi treatment. These changes therefore were
unlikely to account for any difference in mortality or detection
of nascent collagen protein.
To address how NEi reduced mortality, we assessed whether
SSR69071 prevented apoptosis or enhanced IEC proliferation.
Apoptosis, as indicated by cleaved caspase 3 (CC3) staining,
was not increased in Tslp+/+ or Tslp/ mice 8 (Figure S6B) or
10 (Figure 5D) days post-DSS. Ki67 staining revealed signifi-
cantly reduced proliferation 8 and 10 days post-DSS in Tslp/
mice.
Although this proliferation defect was not restored by
SSR69071 treatment 8 days post-DSS (Figure S6C), IEC prolifer-
ation was restored 10 days post-DSS in NEi-treated Tslp/
mice (Figures 5C and 5E). Inhibition of NE restored nascentImmunity 35, 223–235collagen 8 and 10 days post-DSS
(Figures S6A and S6E). More importantly,
treatment normalized PGRN protein
8 days post-DSS (e.g., 2 days of NEi
treatment) (Figure S6D) and 10 days
post-DSS (4 days NEi treatment) (Fig-
ure 5F). This occurred at a posttranscrip-
tional level, as indicated by the fact that
PGRNmRNA expression did not increase
with NEi treatment (Figures S6F and S7).
Thus, although the NEi was effective
within 2 days of treatment, at least
4 days of increased PGRN stability was
required before an effect on IEC prolifera-
tion could be observed. TSLP-induced
SLPI is required to regulate NE activity
and subsequently PGRN availability,
leading to healing and ultimately the
survival of DSS-treated Tslp/ mice.
TLSPR on Cells of a
Nonhematopoietic Lineage Is
Sufficient for Recovery from DSS
Colitis
We assessed the sites of TSLP and SLPI
production in situ by performing immuno-fluorescence on colonic tissue. To this end, staining for epithelial
cadherin (E-cadherin; green), a protein that localizes to the
periphery of IEC, SLPI (red), and TSLP (blue), was performed
(Figure 6A). TSLP was predominantly expressed in IEC
(E-cadherin+ cells, adjacent to asterisk). In contrast, SLPI
expression can be found in TSLP+ IEC (adjacent to dagger)
and in cells of the lamina propria (arrowheads).
To determine whether TSLP-induced signaling in immune cells
was required for resolution of colitis, we constructed BM
chimeras by reconstituting irradiated WT mice with BM from
Crlf2+/+ or Crlf2/ mice and subjected them to DSS. The
severity of colitis was not enhanced in WT recipients of Crlf2/
bone marrow (Crlf2// Crlf2+/+) compared to WT (Crlf2+/+/
Crlf2+/+) chimeras, 8 days post-DSS. Weight loss (Figure 6B),
colon length (Figure 6C), and histological damage (Figure 6E)
were similar in recipients of Crlf2+/+ or Crlf2/ BM, indicating
that the absence of TSLPR on cells of hematopoietic origin, August 26, 2011 ª2011 Elsevier Inc. 229
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mortality was not observed in recipients of Crlf2/ BM after
DSS colitis compared to Crlf2+/+ BM recipients. Furthermore,
no reduction in collagen deposition (Figure 6D) and equivalent
SLPI mRNA expression was detected in Crlf2// Crlf2+/+
andCrlf2+/+/ Crlf2+/+ (Figure 6F) BM chimeras. Together, these
data demonstrate that TSLP aids in resolution of colonic inflam-
mation through cells of a nonhematopoietic lineage.
TSLPR Is Expressed and Functional on the Surface
of Intestinal Enterocytes
IEC were isolated from the duodenum, jejunum, terminal ileum,
and middistal colon and assessed for TSLPR by flow cytometry.
Isolated and enriched epithelial cells from jejunum, terminal
ileum, and colon were TSLPR+ (Figure 7A) and confirmed
in situ by IHC (Figure 7B). TSLPR was not expressed on fibro-
blasts (aSMA, E-cadherin, vimentin+) or myofibroblasts
(aSMA+, E-cadherin, vimentin+) isolated from the intestinal
stroma (Figure 7C). TSLPR on IEC is functional, as shown by
the fact that stimulation with rmTSLP induced AKT (S473) and
ERK (T208) phosphorylation in Crlf2+/+ but not Crlf2/ IEC
(Figure 7D).
In order to determine the kinetics of signal transduction, we
stimulated the mouse IEC line mICcl2 with rmTSLP. Stimulation
elicited ERK1/2 and AKT phosphorylation within 10 min and the
downstream target, Foxo3a, within 30 min (Figure 7E). Phos-
phorylation of Foxo3a resulted in increased expression of the
antiapoptotic BCL2 within 2 hr poststimulation, whereas MCL-1
was not altered (Figure 7F). This suggests that TSLP can alter
apoptosis in IEC by inducing antiapoptotic genes expression.
This reductionist approach was further utilized to determine
whether TSLP stimulation of IEC was sufficient to induce SLPI
expression. mICcl2 monolayers stimulated with rmTSLP-
increased SLPI mRNA was within 1 hr after stimulation (Fig-
ure 7G) and increased protein expression after 2 hr (Figure 7F).
Together these data demonstrate that TSLP can directly elicit
signaling in IEC and induce the expression of SLPI.
DISCUSSION
This study highlights the critical role for TSLP in colonic healing
after transient inflammation. Our findings demonstrate that lack
of TSLP ligand or receptor does not enhance disease severity,
but prevents resolution, resulting in death. Increased mortality
was due to unrestrained NE activity increasing turnover of pro-
granulin, a protein that induces IEC proliferation. The underlying
mechanism for this dysregulated NE activity was found to be due
to an inability to increase SLPI expression after DSS-induced
inflammation. TSLP-elicited signaling is not restricted to immune
cells, with stimulation through TSLPR on IEC activating intracel-
lular signaling and SLPI expression.
Immunity was not altered in Tslp/mice in the steady state or
after the induction of an immune response. No Th1 or Th17 cell
bias was observed in naive mice or during DSS-induced colitis
systemically (serum or splenocytes) or within the mucosal envi-
ronment (MLN or colon). Lack of enhanced inflammation was
not model specific, as shown by the fact that deficiency in
TSLP signaling did not increase the severity of a T cell-depen-
dent colitis by enhanced Teff (i.e., increased Th1 cytokine230 Immunity 35, 223–235, August 26, 2011 ª2011 Elsevier Inc.production) or decreased Treg cell function. It is important to
note that although TSLP can potentiate Th2 cell responses (Ito
et al., 2005), Tslp/ orCrlf2/mice remained capable of gener-
ating Th2 cytokines. In accordance with our data, Th2 cell
responses remained intact after infection of Crlf2/ mice with
an intestinal helminth (Massacand et al., 2009). Moreover, oral
vaccination against OVA induces equivalent OVA-specific Th2
cell responses in WT and Crlf2/ mice (Bla´zquez et al., 2010).
Therefore, TSLP is not required for Th2 cell responses, and the
absence of TSLP does not necessarily result in Th1 cell-biased
immune responses.
To determine whether death in Tslp/ mice was due to overt
inflammation, downstream proinflammatory signaling cascades
were studied. TSLP deficiency did not alter the expression of
negative regulators of proinflammatory cytokine signaling, elim-
inating a role for uninhibited NF-kB-regulated gene expression
(e.g., iNOS, IL-6, TNF-a). Although reduced healing of the intes-
tinal mucosa and an inability to limit colonic inflammation has
been observed in Anxa1/ (Babbin et al., 2008) and Ptges2/
(Morteau et al., 2000) mice, TSLP deficiency did not impact
expression of these genes, indicating that the resolution defect
is independent of these factors. As a whole, our data demon-
strate that impaired recovery from DSS colitis is not simply due
to aberrant cytokine production.
We excluded the possibility that impaired host defenses pre-
vented the ability to recover from DSS colitis and increased
mortality in Tslp/ mice. Naive and DSS-treated Tslp/ mice
did not have increased bacterial translocation to the MLN or
spleen. Increased translocation is a common observation in
mice with impaired host defenses because of ablation of genes
such as Myd88 (Slack et al., 2009). Because the intestinal
mucosa is under continuous immune surveillance that results
in migration of DC laden with commensal bacteria to the MLN
(Fukata et al., 2005; Macpherson and Uhr, 2004), it is improbable
that increased bacteria within the colonic mucosa occurred
without a parallel increase in MLN. Altered host defenses can
also perturb the composition of the microbiota (Lupp et al.,
2007). As an example of this, Nod2/ mice have reduced anti-
bacterial peptides, increasing specific commensal populations
(Petnicki-Ocwieja et al., 2009). We noted no significant effect
on the microbiota in Tslp/ or Crlf2/ compared to WT mice.
In keeping with this, no difference was observed in the REG
family of c-type lectins that function as antimicrobial peptides
(Pickert et al., 2009). We also noted no deficiency in the recruit-
ment of neutrophils to the colon after DSS colitis or into the peri-
toneum after challenge with pathogen-associated molecular
patterns. Critically, mouse norovirus and Helicobacter sp. were
not detected in our mice, because both can exacerbate the
severity of intestinal inflammation (Cadwell et al., 2010). There-
fore, it is unlikely that Tslp/mice have a defect in host defense,
and instead the contribution of microbiota in different animal
facilities (Friswell et al., 2010) may play a pivotal role in the differ-
ences between previous studies (Taylor et al., 2009).
Repair of the epithelium occurs in at least two phases: the
rapid restitution phase and a slower regeneration period.
Whereas restitution involves spreading of epithelial cells to fill
gaps in the damagedmucosa, regeneration requires cell prolifer-
ation, deposition of proteins including collagen around the
wound site (Taupin and Podolsky, 2003), and contraction by
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Figure 7. TSLPR Is Expressed and Functional on IEC
(A) Primary IEC were stained for flow cytometry for epithelial markers (E-cadherin+ CD3, B220, F4/80) and TSLPR.
(B) IHC was performed on colonic tissue sections with TSLPR antibody.
(C) TSLPR expression was assessed on fibroblasts (Vimentin+, alpha-smooth muscle actin- [a-SMA], E-cadherin CD3 CD11b B220 F4/80) or myofibro-
blasts (Vimentin+ a-SMA+, E-cadherin CD3 CD11b B220 F4/80) from Crlf2+/+ (gray fill, black outline) and Crlf2/ (negative control, red line) mice.
(D) ERK and AKT phosphorylation in primary IEC from Crlf2+/+ and Crlf2/ mice were assessed after stimulation with rmTSLP (50 ng/mL, 30 min; mean ± SD,
*p < 0.05, ANOVA).
(E) AKT Foxo3A and ERK phosphorylation were assessed in mICc12 cells by immunoblotting after stimulation with rmTSLP for the indicated times (50 ng/mL).
(F) Expression of antiapoptotic genes including the Foxo3a-regulated BCL2 and SLPI were determined after exposure to rmTSLP.
(G) SLPI mRNA in mICcl2 cells after TSLP exposure was determined by qRT-PCR (n = 3, mean ± SD, *p < 0.05, ANOVA).
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TSLP Is Required for Recovery after Colitismyofibroblasts. Deposition of structural proteins is a tightly
controlled process; dysregulation results in fibrosis or fistula
development resulting from increased or insufficient ECM
protein deposition, respectively (Rieder et al., 2007). This
process is regulated by the rate of collagen synthesis and thebalance between proteolytic enzymes and their endogenous
inhibitors. Highlighting that this balance was altered in
DSS-treated Tslp/ mice, reduced collagen was detected
by histological staining and by Sircol assay without concomi-
tant decreases in collagen mRNA expression. These dataImmunity 35, 223–235, August 26, 2011 ª2011 Elsevier Inc. 231
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TSLP Is Required for Recovery after Colitisdemonstrated that the reduced collagen deposition was due to
enhanced, localized enzymatic activity resulting in collagen turn-
over. In accordance with a previous report (Castaneda et al.,
2005), we observed increased MMP activity during overt colonic
inflammation; however, this occurred irrespective of genotype,
indicating that the increased mortality is MMP independent.
Degradation of collagen can also occur by NE (Zhu et al.,
2001), an enzyme found in abundance in samples from patients
with IBD (Langhorst et al., 2008). Colonic tissue assayed at the
peak of disease demonstrated significantly enhanced NE activity
in DSS-treated Tslp/ compared toWTmice, without increased
NE expression. Increased enzymatic activity without a parallel
increase in NE expression indicated a defect in an endogenous
regulator.
A profound reduction in SLPI mRNA and protein were
observed in the colon of Tslp/ mice post-DSS. This inability
to increase SLPI expression after DSS colitis and to control NE
activity decreased mucosal healing and ultimately increased
mortality. Indeed, inhibition of NE with a selective inhibitor or
rSLPI significantly improved survival in Crlf2/mice. In support
of this hypothesis for regulation of wound healing by SLPI,
increased NE activity delayed recovery in Slpi/ mice after
dermal injury (Ashcroft et al., 2000). SLPI influences the balance
between host defense and tissue repair by regulating NE-medi-
ated conversion of progranulin to granulin. These proteins exert
opposing physiological functions: progranulin induces epithelial
cell proliferation and reduces neutrophil activity and granulin
inhibits proliferation and increases IL-8 production (human cell
lines), neutrophil recruitment, and activation (Kessenbrock
et al., 2008; Zhu et al., 2002). To delineate the role of enhanced
NE activity in the failure to recover from DSS colitis in Tslp/
mice, we assessed the impact of NE inhibition during the
recovery phase. IEC proliferation was significantly reduced
8 days post-DSS that was normalized after 4 days of
SSR69071 treatment. This inhibition of NE activity restored
nascent collagen protein and PGRN in DSS-treated Tslp/
mice beginning 2 days after treatment. In accordance with previ-
ously published in vitro data, where PGRN increased epithelial
cell proliferation after 3 days (Zhu et al., 2002), IEC proliferation
occurred after 4 days of treatment subsequent to inhibition of
NE and stabilization of the PGRN protein. Together our data indi-
cate that TSLP-induced SLPI dictates the balance between host
defense and tissue regeneration and consequently aids mucosal
healing after colonic inflammation by modulating NE activity.
Although TSLP has been primarily thought to exert physiolog-
ical effects through TSLPR on B cells, T cells, and DCs, the
contribution of this receptor on nonhematopoietic cells was eval-
uated in the resolution of colitis. By using BM chimeras, TSLPR
on nonhematopoietic cells was sufficient for SLPI expression
and survival. Supporting a role for nonhematopoietic cells, func-
tional TSLPR is expressed on the surface of primary IEC and
a mouse IEC line. Stimulation through this receptor initiates acti-
vation of both ERK and AKT signaling and SLPI expression. Resi-
dent colonic fibroblasts or myofibroblasts would seem to be
excluded from this population of cells that can directly respond
to TSLP, because they lack TSLPR. In assessing TSLP and
SLPI production in situ, both proteins were prominently coex-
pressed in colonic IEC with some SLPI expression localized to
cells in the lamina propria. As previously reported, these are232 Immunity 35, 223–235, August 26, 2011 ª2011 Elsevier Inc.probably macrophages (Nakamura et al., 2003) and DCs (Sam-
som et al., 2007), although it would appear that IEC are the
predominant source of colonic SLPI. Therefore, TSLP can act
on IEC in an autocrine manner that is beneficial to intestinal resti-
tution and healing.
Here we propose a model whereby TSLP acts as a key facili-
tator inwound repair after intestinal injury. BecauseTSLPexpres-
sion by IEC is enhanced after TLR stimulation or proinflammatory
cytokines (Zaph et al., 2007), it is conceivable that after DSS-
induced epithelial injury, exposure to the luminal contents
increases TSLP expression in adjacent IEC. TSLP produced in
thismanner can act directly on epithelial or stromal cells to induce
SLPI gene expression, creating a local tissue environment that
favors healing and resolution of inflammation. This is a nonredun-
dant role of TSLP in the colonic mucosa and one that does not
involve restraining of Th1 or Th17 cell immune responses.
EXPERIMENTAL PROCEDURES
Mice
Tslp/mice were generated by a conventional targeting strategy by inserting
an eGFP and a neomycin cassette into exon 2 five codons after the transcrip-
tion start of the TSLP gene. Insertion of the targeting vector deletes a portion of
exon 2 and all of exons 3 and 4. Deletion of TSLP in Tslp/ mice was
confirmed by Southern blotting and PCR with primers spanning the junction
between exon 2 and the eGFP-NeoR insert (data not shown). Mice were back-
crossed to C57BL/6 for at least 10 generations, with both males and females
used. TSLPR-deficient (Crlf2/) mice were described previously (Al-Shami
et al., 2005). Rag1/ mice (Jackson) were backcrossed to C57BL/6 mice
for at least 10 generations.
Hematological Analysis
Blood collected by cardiac puncture was added to an EDTA-containing tube
and was analyzed with a HEMAVET instrument (Abaxis, Union City, CA).
Induction of Colitis
Colitis was induced by addition of dextran sodium sulfate (DSS; 36,000–
50,000 MW; MP Biomedicals, Solon, OH) to the drinking water for 5 days, fol-
lowed by 3 days of normal water. Blood was collected from anesthetized mice
by cardiac puncture.
In subsets of experiments, mice were treated with the NE inhibitor
SSR69071 or vehicle (DMSO) by oral gavage twice daily (3 mg/kg; Tocris, Ellis-
ville, MS). Mice were treated with rSLPI (R&D systems) by gavage in 0.1 M
sodium borate twice daily (Sigma-Aldrich, St. Louis, MO).
Adoptive Transfer
Colitis was induced by the transfer of FACS-sorted CD4+CD45RBhi effector
T cells (4 3 105 cells/mouse). Protection from colitis and hence the capacity
of immunoregulatory CD4+CD45RBlo (2 3 105 cells/mouse) cells was as-
sessed after cotransfer into recipient C57BL/6 Rag1/ mice.
Colitis was assessed by macroscopic and histological scores published
previously (Reardon et al., 2001). All procedures were approved by the Univer-
sity Health Network animal care committee.
Immunization
Micewere immunized with OVA (Grade V, Sigma-Aldrich) in CFA (Fisher Scien-
tific Ottawa, ON) or Alum AlK(SO4)2 (Sigma-Aldrich) by i.p. injection as
described previously (Yip et al., 1999). Serum was obtained 2 weeks later,
with OVA-specific IgG1, and IgG2a was determined by ELISA (Southern
Biotechnology, Birmingham, AL).
Neutrophil Recruitment
Mice were injected i.p. with 100 ng LPS (Sigma Aldrich) or 100 mg of MDP (In-
vivogen, San Diego, CA). The peritoneal cavity was washed with PBS, and
recovered cells were counted, stained, and enumerated by flow cytometry.
Immunity
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Male recipient mice were lethally irradiated (Gammacell 40; MDS Nordion,
Ottawa, ON) by two exposures of 550 rads prior to receiving 13 106 BM cells
from Crlf2/ mice by i.v. and were maintained on Baytril for 2 weeks.
Immunohistochemistry
Tissues were formalin fixed and processed according to standard histological
protocols. Staining with PAS reagent or masson’s trichrome were conducted
according to manufacturer’s instructions (Sigma-Aldrich). Sections were
stained for Ki67 (Lab Vision, Fremont, CA), EMR1 (Life Span Biologicals, Seat-
tle, WA), NIMP (Santa Cruz Biotechnology, Santa Cruz, CA), Cleaved Cas-
pase3 (Cell Signaling Technology, Danvers, MA) with a standard protocol for
development with DAB substrate (VectorLabs, Burlington, ON).
Immunofluorescence
Formalin-fixed paraffin-embedded tissues were stained by a previously pub-
lished protocol (Kaniuk and Brumell, 2010). In brief, rehydrated sections
were subjected to antigen retrieval (citrate buffer, pH 6.0, 90C, 30 min). Slides
were blocked for 1 hr and incubated with anti-E-cadherin (ECMbiosciences,
Versailles, KY), -SLPI, -TSLP (Life Span Biologicals) overnight, washed, and
incubated with appropriate conjugated secondary antibodies Alexa Fluor
488, 546, and 647 (1 hr, RT, Invitrogen). Images were acquired with a Fluoro-
view 1000 confocal microscope (Olympus, Markham, ON).
Real-Time Quantitative PCR
Tissue was homogenized in Trizol (Invitrogen, Burlington, ON) with a Tissue-
Lyser (QIAGEN). RNA was precipitated with LiCl2 and cDNA synthesis was
performed (iScript kit; Bio-Rad, Mississauga, ON). Previously published
primers (Peterson et al., 2010) or primers selected from the primerbank (Span-
didos et al., 2008) (Table S2) were used in qRT-PCR with SyberGreen master
mix (ABI). Data were analyzed by the 2DDCT method normalizing to gapdh.
Assessment of Microbiota
Microbial DNA was extracted with a QIAamp DNA stool kit (QIAGEN) accord-
ing to manufacturer’s specifications. DNA eluted from the spin columns was
quantified, and qRT-PCR was performed with microbial primers to 16S
rDNA (Table S2). Data are presented as percentage relative to eubacteria.
Flow Cytometry
Spleens and lymph nodes were dissociated mechanically, and red blood
cell lysis was performed on spleens with ACK buffer (Sigma-Aldrich). For
splenic DC, spleens were injected with collagenase/DNase (37C, 30 min).
Cells were counted, and 1 3 106 cells were stained with anti-B220, -CD3,
-CD11b, -CD40, -CD80, -CD86, -F4/80, -IgA, -MHCII (BDBiosciences,Missis-
sauga, ON), -CD11c, -pDCA-1 (eBioscience, San Diego, CA), and -TSLPR
(R&D systems, Minneapolis, MN).
Intracellular staining for Foxp3 and IFN-g were conducted according to
manufacturers’ instructions (Biolegend and eBioscience, respectively). Phos-
phoflow was performed with anti-pSTAT5, -pERK1/2 (BD Biosciences),
or -pAKT (Cell Signaling Technology). Vimentin (Cell signaling Tech.) and
aSmooth Muscle Actin (Milipore) were labeled with Alexa Fluor 405 and 488,
respectively, with a Zenon labeling kit (Invitrogen).
Data were acquired on a CantoII (BDBiosciences) and analyzedwith FlowJo
(Tree star, Ashland OR).
Cytometric Bead Array
Serum cytokine concentrations were evaluated with amouse Th1/Th2/Th17 kit
(BD Biosciences) according to the manufacturer’s instructions. Samples were
acquired on a FACsArray and analyzed with CBA software (BD Biosciences).
In vivo Permeability
Mice were starved overnight with free access to water and gavaged the next
morning with 4.4KDa FITC-Dextran (Sigma-Aldrich). Blood was collected
4 hr postgavage as described above and read on a Flex Station3 (Molecular
Devices, Sunnyvale, CA).Bacterial Translocation
Spleens or MLN were weighed and homogenized in 500 ml of sterile PBS con-
taining 0.1% Triton X-100 (w/v). Samples were serially diluted in PBS, plated
on 5% Sheep’s blood agar, and grown overnight.
MMP and Neutrophil Elastase Assays
Snap frozen tissue was homogenized by TissueLyser (QIAGEN). MMP activity
was assayed with a generic MMP assay kit (AnaSpec) according to manufac-
turer’s instructions. Neutrophil elastase activity was assessed in a similar
fashion, except that Rhodamine 110, bis-CBZ-L-alanyl-L-alanyl-L-alanyl-L-
alanine amide (Invitrogen) was used as the substrate.
Sircol Collagen Assay
Collagen was quantified with the Sircol assay according to manufacturer’s
instructions. Colonic protein was incubatedwith Sirius redwith gentle agitation
(0.5 hr, RT). Dye-bound collagen was centrifuged, washed, and resolubilized
with alkaline buffer. Collagen concentration was determined by measuring
the absorbance at 555 nm (Flex Station).
Cells
Cells were stimulated with recombinant mouse TSLP (R&D systems).
Enrichment of Epithelial Cells, Fibroblasts, and Myofibroblasts
Intestinal tissues were opened, washed in PBS, and cut into 0.5 mm pieces.
Tissues were incubated with cell recovery solution (BD Biosciences) (Perreault
and Beaulieu, 1998). Epithelial cells were stained immediately for flow cytom-
etry or enriched by negative selection with the BD Imag system (BD Biosci-
ences) to remove CD11b+, CD11c+, CD3+, B220+ cells. For phosphoflow, cells
were incubated in optiMEM for 15 min and restimulated with 50 ng/mL of
rmTSLP for 30 min prior to analysis as described above.
Fibroblasts andmyofibroblasts were dissociated by collagenase/dispase as
described previously (Evans et al., 1992; Fruchtman et al., 2005). Cells were
surface stained for E-cadherin, CD11b, CD11c, F480, CD3, B220, fixed with
formaldehyde (4% v/v), and treated with cytoperm (BD Biosciences) for intra-
cellular staining of aSMA and vimentin as described above.
Immunoblotting
Immunoblotting was performed according to a standard protocol. Blots were
incubated with anti-SLPI (Santa Cruz Biotechnology, Santa Cruz, CA),
-Foxo3A, -Phospho-Foxo3A (T32), -Phospho-AKT, -Phospho-ERK, -BCL2
(Cell Signaling Technology), and -AKT, -ERK, -Tubulin, -MCL (Santa Cruz
Biotechnology).
Statistics and Data Presentation
All statisticswere calculated in Prism 5.0 (GraphPad, La Jolla, CA) and are two-
tailed Student’s t test or ANOVA with Tukey post-test as indicated in the
respective figure legends. All data are presented as mean ± standard
deviation.
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